Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective, orally available SYK inhibitor (IC50 = 9.5 nM) used for the investigation of inflammatory diseases; it inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.